Malcolm Salter - 02 Jul 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Shoaib Ghias, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
02 Jul 2021
Net transactions value
+$13,465
Form type
4
Filing time
07 Jul 2021, 16:30:19 UTC
Previous filing
21 Jun 2021
Next filing
19 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Award $13,465 +339 +2.3% $39.72* 15,182 02 Jul 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021.